GI 254023X: Selective ADAM10 Inhibitor for Vascular and Leukemia Research

Executive Summary: GI 254023X (SKU A4436) is a potent, highly selective ADAM10 metalloprotease inhibitor with an IC₅₀ of 5.3 nM, showing >100-fold selectivity over ADAM17 and no significant water solubility [APExBIO product data]. It blocks ADAM10-mediated cleavage events including fractalkine (CX3CL1) and VE-cadherin, modulating Notch1 signaling and cell adhesion. In vitro, it induces apoptosis and inhibits proliferation in Jurkat T-lymphoblastic leukemia cells; in vivo, it enhances vascular integrity in mice challenged with bacterial toxins. These features make GI 254023X a benchmark tool for studying ADAM10-driven processes in vascular, oncologic, and immunological models [Satir et al., 2020].

Biological Rationale

ADAM10 (A Disintegrin and Metalloproteinase 10, EC 3.4.24.81) is a sheddase enzyme involved in the proteolytic cleavage of diverse membrane proteins, including cytokines, cell adhesion molecules, and signaling receptors. This activity is central to processes such as cell-cell communication, inflammation, and tumor progression (Satir et al., 2020). Aberrant ADAM10 activity contributes to pathological states, including acute T-lymphoblastic leukemia, neurodegeneration, and vascular barrier dysfunction. Selective inhibition of ADAM10 enables targeted modulation of these pathways without broadly affecting related metalloproteases such as ADAM17.

Mechanism of Action of GI 254023X

GI 254023X is a small molecule inhibitor (C₂₁H₃₃N₃O₄, MW 391.5) that binds the catalytic site of ADAM10, blocking substrate access and preventing proteolytic cleavage. The compound exhibits an IC₅₀ of 5.3 nM against human ADAM10, with >100-fold selectivity over ADAM17 under identical assay conditions [APExBIO]. In cellular systems, GI 254023X inhibits ADAM10-mediated cleavage of fractalkine (CX3CL1), Notch1, and VE-cadherin. This reduces downstream signaling (e.g., Hes-1 mRNA) and modulates cell adhesion, proliferation, and survival. In human pulmonary artery endothelial cells (HPAECs), it prevents VE-cadherin cleavage and protects against Staphylococcus aureus α-hemolysin-induced endothelial barrier disruption. In mouse models, intraperitoneal administration at 200 mg/kg/day for 3 days enhances vascular integrity and prolongs survival following lethal toxin challenge.

Evidence & Benchmarks

• GI 254023X inhibits human ADAM10 with an IC₅₀ of 5.3 nM in biochemical assays (APExBIO, product data).
• Demonstrates >100-fold selectivity for ADAM10 over ADAM17 under matched conditions (APExBIO, product page).
• Blocks constitutive fractalkine (CX3CL1) cleavage and Notch1 signaling in Jurkat T-lymphoblastic leukemia cells; modulates Hes-1 mRNA levels (APExBIO, data).
• Induces apoptosis and inhibits proliferation in Jurkat cells in vitro (APExBIO, product info).
• Prevents VE-cadherin cleavage and protects HPAECs from α-hemolysin-induced barrier disruption (APExBIO, product sheet).
• Enhances vascular integrity and increases survival in BALB/c mice after lethal bacterial toxin exposure, when administered at 200 mg/kg/day i.p. for 3 days (APExBIO, data).
• Does not inhibit β- or γ-secretases, distinguishing it from BACE or γ-secretase inhibitors used in Alzheimer's research (Satir et al., 2020).

For a comparison of workflow strategies and troubleshooting, see this guide, which focuses on unlocking precise control of sheddase activity; the present article extends these findings by providing new quantitative benchmarks and mechanistic context.

Applications, Limits & Misconceptions

GI 254023X is primarily intended for research on ADAM10-mediated processes in oncology, vascular biology, and immunology. It is a reference tool for dissecting Notch1 signaling, cell-cell adhesion, and acute T-lymphoblastic leukemia pathways. Its selectivity profile reduces off-target effects compared to broad-spectrum metalloprotease inhibitors.

Common Pitfalls or Misconceptions

• GI 254023X does not inhibit β-secretase (BACE1) or γ-secretase; it cannot substitute for these in Alzheimer's disease models focused on Aβ production (Satir et al., 2020).
• It is insoluble in water; stock and working solutions must be prepared in DMSO or ethanol with warming and sonication as needed (APExBIO).
• Long-term storage of solutions is not recommended; store solid at -20°C and use fresh solutions for reproducibility.
• GI 254023X is for preclinical research only; it is not suitable for clinical or diagnostic use.
• Inhibition of ADAM10 may not recapitulate all downstream effects of broader metalloprotease blockade; pathway validation is essential for each system.

For workflow optimization and troubleshooting, see this cell assay guide, which offers practical steps for cell viability and apoptosis assays. The present article clarifies the molecular selectivity profile underpinning those recommended protocols.

Workflow Integration & Parameters

• Storage: Store as a solid at -20°C; avoid repeated freeze-thaw cycles.
• Solubility: Soluble to ≥42.6 mg/mL in DMSO and ≥46.1 mg/mL in ethanol; insoluble in water.
• Stock Preparation: Prepare stock solutions in DMSO at concentrations >10 mM; warming and sonication can aid dissolution.
• Recommended Usage: Use freshly prepared solutions; do not store diluted stocks for more than one day unless validated for stability.
• Assay Compatibility: Validated for cell viability, proliferation, apoptosis, and vascular integrity assays in vitro and in vivo.
• Dosage Example: 200 mg/kg/day i.p. for 3 days in BALB/c mice improves survival after toxin challenge.

For a detailed, scenario-driven guide to robust ADAM10 inhibition in cell viability assays, see this article. The current overview updates that resource with new in vivo benchmarks and clarifies selectivity parameters.

Conclusion & Outlook

GI 254023X, supplied by APExBIO, is a validated, highly selective ADAM10 inhibitor for advanced biomedical research. Its nanomolar potency and well-characterized selectivity profile enable precise modulation of ADAM10-mediated events in oncology, vascular, and immunological contexts. The compound is suited for dissecting cell signaling, apoptosis induction, and endothelial barrier models. GI 254023X is not appropriate for clinical or diagnostic use, nor for inhibition of β- or γ-secretases. Ongoing preclinical development and expanding literature will further clarify its utility and limitations. For product specifications and ordering, refer to the GI 254023X product page.